| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7316067 | SUNOVION RESP | Forming a perforate membrane by laser drilling and a subsequent electro-polishing step |
Sep, 2022
(1 year, 15 days ago) | |
| US8511581 | SUNOVION RESP | Fluid droplet production apparatus and method |
Nov, 2023
(a month from now) | |
| US7458372 | SUNOVION RESP | Inhalation therapy device |
Nov, 2024
(1 year, 1 month from now) | |
| US7931212 | SUNOVION RESP | Fluid droplet production apparatus and method |
Nov, 2025
(2 years from now) | |
| US11278683 | SUNOVION RESP | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Aug, 2026
(2 years from now) | |
| US9265900 | SUNOVION RESP | Disposable ampoule for an aerosol generating device |
Dec, 2028
(5 years from now) | |
| US10940110 | SUNOVION RESP | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations |
Feb, 2029
(5 years from now) | |
| US9789270 | SUNOVION RESP | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Oct, 2030
(7 years from now) | |
| US9168556 | SUNOVION RESP | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer |
Sep, 2032
(8 years from now) | |
| US9604018 | SUNOVION RESP | Aerosol therapy device |
May, 2033
(9 years from now) | |
| US10376661 | SUNOVION RESP | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element |
Sep, 2035
(11 years from now) | |
| US10688518 | SUNOVION RESP | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator |
Nov, 2036
(13 years from now) | |
| US10744277 | SUNOVION RESP | Aerosol delivery device and method of operating the aerosol delivery device |
Dec, 2036
(13 years from now) | |
Lonhala Magnair Kit is owned by Sunovion Resp.
Lonhala Magnair Kit contains Glycopyrrolate.
Lonhala Magnair Kit has a total of 13 drug patents out of which 1 drug patent has expired.
Expired drug patents of Lonhala Magnair Kit are:
- US7316067
Lonhala Magnair Kit was authorised for market use on 05 December, 2017.
Lonhala Magnair Kit is available in solution;inhalation dosage forms.
Lonhala Magnair Kit can be used as a method of using an aerosol delivery device to aerosolize glycopyrrolate for the treatment of chronic obstructive pulmonary disease (copd), long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).
The generics of Lonhala Magnair Kit are possible to be released after 07 December, 2036.
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd); A method of using an aerosol delivery device to aerosolize glycopyrrolate for the ...
Dosage: SOLUTION;INHALATION
LONHALA MAGNAIR KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic